Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Amgen, Novartis, Banner Institute Discontinue Alzheimer's Prevention Clinical Research Program

share with twitter share with LinkedIn share with facebook
share via e-mail
07/11/2019 | 05:16pm EDT

By Stephen Nakrosis

Amgen Inc. said Thursday a clinical research program it was conducting into Alzheimer's prevention with Novartis AG (NVS) and the Banner Alzheimer's Institute was being discontinued.

The program was studying the effect of the BACE1 inhibitor CNP520, or umibecestat, as part of the Alzheimer's Prevention Initiative Generation Program, Amgen said. Specifically, the program was researching the safety and efficacy of CNP520 for the prevention or delay of the onset of Alzheimer's disease in certain patients.

Amgen said "After review of clinical data, the sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk."

Amgen and Novartis formed a global collaboration in 2015 to develop and commercialize pioneering treatments in the field of migraine and Alzheimer's disease. The studies are sponsored by Amgen and Novartis, in collaboration with Banner Alzheimer's Institute, Amgen said.

David Reese, executive vice president of Research and Development at Amgen, said "Although the outcomes of the research program did not lead to the results we aimed for, we are committed to sharing our findings to help advance the medical and scientific community one step further toward finding a prevention for this devastating disease."

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN -0.71% 203.21 Delayed Quote.5.13%
NOVARTIS 0.08% 86.4 Delayed Quote.16.20%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
07:58aNOVARTIS : announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase ..
07:52aINCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
06:17aFactbox - How are businesses preparing for a 'no-deal Brexit'?
10/15NOVARTIS : Sandoz and Pear Therapeutics announce Pear will solely commercialize ..
10/14EUROPE : European stocks hit pause as trade doubts linger
10/11NOVARTIS : data show Cosentyx treatment results in rapid and sustained resolutio..
10/10NOVARTIS : data show Cosentyx® treatment results in rapid and sustained resoluti..
10/09NOVARTIS : real-world evidence confirms high efficacy, long-term response and fa..
10/09NOVARTIS : STEP Program now accepting submissions for proposals that address unm..
10/09NOVARTIS : real-world evidence confirms high efficacy, long-term response and fa..
More news
Financials (USD)
Sales 2019 46 902 M
EBIT 2019 13 829 M
Net income 2019 9 642 M
Debt 2019 17 425 M
Yield 2019 3,42%
P/E ratio 2019 18,2x
P/E ratio 2020 19,8x
EV / Sales2019 4,59x
EV / Sales2020 4,28x
Capitalization 198 B
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,12  $
Last Close Price 86,40  $
Spread / Highest target 24,4%
Spread / Average Target 8,93%
Spread / Lowest Target -6,83%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS16.20%198 243
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
PFIZER-16.38%201 883
AMGEN5.13%122 735